2023 World Conference on Lung Cancer (Posters)-EP08.03. Nivolumab Plus Ipilimumab in Relapsed Stage III Non-small Cell Lung Cancer after Durvalumab Following Chemoradiotherapy

EP08.03. Nivolumab Plus Ipilimumab in Relapsed Stage III Non-small Cell Lung Cancer after Durvalumab Following Chemoradiotherapy - PDF(Abstract)

Back to course

Pdf Summary

A retrospective study was conducted to assess the clinical significance of nivolumab plus ipilimumab in patients with recurrent non-small cell lung cancer (NSCLC) after durvalumab following chemoradiotherapy. The study found that nivolumab plus ipilimumab containing regimens may be a probable and efficient treatment alternative for patients with locally advanced NSCLC relapsing after durvalumab following chemoradiotherapy. The study included 30 patients, with a median age of 72 years, who received nivolumab plus ipilimumab-containing regimens after consolidation durvalumab following chemoradiotherapy. The median progression-free survival (PFS) was 4.4 months and the median overall survival (OS) was 18.5 months. The 6-month PFS rate was 46.7% and the overall response rate (ORR) was 23.3%. Longer treatment duration of durvalumab was significantly associated with better PFS and OS. Common adverse events included hepatitis, dermatitis, and thyroid dysfunction. Grade 3 adverse events occurred in 10% of the patients. The study suggests that nivolumab plus ipilimumab may be particularly effective in patients who have received durvalumab for a longer time.

Asset Subtitle

Takaaki Tokito

Meta Tag

Speaker Takaaki Tokito

Topic Local-Regional NSCLC: Novel Therapies & Trials

Keywords

retrospective study

clinical significance

nivolumab

ipilimumab

non-small cell lung cancer

durvalumab

chemoradiotherapy

progression-free survival

overall survival

adverse events